Genetic polymorphisms in catechol-O-methyltransferase, menopausal status, and breast cancer risk

Cancer Res. 1998 May 15;58(10):2107-10.

Abstract

Polymorphic catechol-O-methyltransferase (COMT) catalyzes the O-methylation of estrogen catechols. In a case-control study, we evaluated the association of the low-activity allele (COMT(Met)) with breast cancer risk. Compared to women with COMT(Val/Val), COMT(Met/Met) was associated with an increased risk among premenopausal women [odds ratio (OR), 2.1; confidence interval (CI), 1.4-4.3] but was inversely associated with postmenopausal risk (OR, 0.4; CI, 0.2-0.7). The association of risk with at least one low-activity COMT(Met) allele was strongest among the heaviest premenopausal women (OR, 5.7; CI, 1.1-30.1) and among the leanest postmenopausal women (OR, 0.3; CI, 0.1-0.7), suggesting that COMT, mediated by body mass index, may be playing differential roles in human breast carcinogenesis, dependent upon menopausal status.

Publication types

  • Research Support, U.S. Gov't, Non-P.H.S.
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Body Mass Index
  • Breast Neoplasms / enzymology*
  • Breast Neoplasms / genetics
  • Case-Control Studies
  • Catechol O-Methyltransferase / genetics*
  • Female
  • Humans
  • Menopause*
  • Middle Aged
  • Neoplasm Proteins / genetics*
  • Polymorphism, Genetic
  • Postmenopause
  • Premenopause
  • Risk Assessment

Substances

  • Neoplasm Proteins
  • Catechol O-Methyltransferase